RedHill Biopharma
8045 Arco Corporate Drive
Suite 200
Raleigh
NC
27617
United States
Website: http://www.redhillbio.com/
477 articles about RedHill Biopharma
-
Phil and RedHill Biopharma Partner to Increase Access to Talicia®
7/6/2023
Phil Inc. , a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform.
-
RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
6/12/2023
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its first quarter 2023 financial results and operational highlights.
-
RedHill Provides R&D Update
5/22/2023
RedHill has elected to terminate RHB-204's U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107 late-stage development for outpatient treatment of COVID-19.
-
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
5/15/2023
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has received a written notification from the Nasdaq Stock Market LLC dated May 9, 2023 indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares set forth in the Nasdaq Rules for continued Nasdaq listing.
-
RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week
5/9/2023
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced two distinct sets of new Talicia[3] data focused on generic non-bioequivalence and on dosing regimens.
-
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting
5/1/2023
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the granting of two new EU and U.S. patents for RHB-102 (BEKINDA)1 and opaganib2, respectively, in the oncology setting.
-
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
4/28/2023
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its fourth quarter and full year 2022 financial results and operational highlights.
-
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
4/11/2023
RedHill Biopharma Ltd. announced that it received confirmation from The Nasdaq Stock Market LLC that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450 for continued Nasdaq listing, and is now compliant with applicable listing standards for continued Nasdaq listing.
-
RedHill Biopharma Announces $6 Million Registered Direct Offering
3/30/2023
RedHill Biopharma Ltd. announced that it has entered into a definitive agreement for the purchase and sale of 1,500,000 of the Company's American Depositary Shares, each ADS representing four hundred ordinary shares, series A warrants to purchase up to an aggregate of 1,500,000 ADSs and series B warrants to purchase up to an aggregate of 1,500,000 ADSs at a purchase price of $4.00 per ADS and associated warrants, in a registered direct offering.
-
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
3/16/2023
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it plans to implement a ratio change of the Company's American Depositary Shares to its non-traded ordinary shares from the current ratio of one ADS representing ten ordinary shares to a new ratio of one ADS representing four hundred ordinary shares.
-
RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor
3/9/2023
RedHill Biopharma Ltd. announced agreement, with a single investor, for the issuance of convertible promissory note in the principal amount of up to $6 million, convertible into American Depositary Shares and warrants to purchase ADSs of the Company, pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended.
-
RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program
2/28/2023
RedHill Biopharma Ltd. announced that the Radiation and Nuclear Countermeasures Program, of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has selected opaganib1 for the nuclear medical countermeasures product development pipeline as a potential treatment for Acute Radiation Syndrome.
-
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
2/28/2023
RedHill Biopharma Ltd. has selected opaganib[1] for the nuclear medical countermeasures product development pipeline as a potential treatment for Acute Radiation Syndrome (ARS).
-
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
2/16/2023
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that following a positive pre-MAA meeting it plans to submit a Marketing Authorisation Application (MAA) to the UK Medicines & Healthcare products Regulatory Agency (MHRA) seeking approval for RHB-102.
-
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
2/16/2023
RedHill Biopharma Ltd. today announced that following a positive pre-MAA meeting it plans to submit a Marketing Authorisation Application (MAA) to the UK Medicines & Healthcare products Regulatory Agency (MHRA) seeking approval for RHB-102 (Bekinda)[i] for oncology support (management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.
-
RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome
2/15/2023
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the positive outcome of a scheduled Type B meeting with the U.S. Food and Drug Administration (FDA) for the development of opaganib for Acute Radiation Syndrome (ARS) in which the FDA provided guidance on opaganib's developmental pathway to potential approval under the Animal Rule.
-
RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik®
2/6/2023
RedHill Biopharma Ltd. today announced the extinguishment of all RedHill's debt obligations (including all principal, interest, revenue interest, prepayment premiums and exit fees) under the Credit Agreement between RedHill Biopharma Inc. and HCR dated February 23, 2020 (as amended) in exchange for the transfer of its rights in Movantik® (naloxegol) to Movantik Acquisition Co., an affiliate of HealthCare Royalty ("HCR").
-
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
1/26/2023
RedHill Biopharma Ltd. today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the granting of a patent covering RHB-204's1 oral fixed-dose combination.
-
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
1/3/2023
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced publication of positive data from a Phase 2 study of once-daily oral investigational RHB-107 (upamostat)[2] in non-hospitalized symptomatic COVID-19 patients.
-
RedHill Biopharma Closes $8.0 Million Underwritten Public Offering
12/6/2022
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the closing of an underwritten public offering with gross proceeds to the Company of approximately $8.0 million, before deducting underwriting discounts and other expenses payable by the Company.